What Is the Life Expectancy With Friedreich Ataxia Today?

Does Friedreich ataxia shorten your lifespan? Yes, Friedreich ataxia (FA) generally shortens lifespan, but life expectancy is highly variable and depends heavily on how the disease affects your heart, your age when symptoms began, and other health factors. While historical data often painted a very limited picture of survival, modern specialized care—particularly proactive management of cardiac complications—aims to improve quality of life and limit disease progression. Today, many people with FA live well into their 50s, 60s, or beyond, especially those with late-onset FA, though an effect on absolute lifespan from recent treatments remains an active area of study.

Understanding Survival Statistics

There is no precise way to predict an individual lifespan for someone diagnosed with Friedreich ataxia. When reading about life expectancy, it is important to understand that published numbers come from different study populations (cohorts) and eras, and they measure different things. None of these statistics can predict your personal future.

• Historical vs. Modern Estimates: Some older publications cite a median life expectancy of around 35 years ^[1]. A retrospective study in Brazil found an average age of death of 33 years among the patients who passed away ^[2]. However, these are averages from specific groups, not universal rules. More contemporary, large-scale studies looking at groups of patients over a 10-year period (a measure of how many people survive during that specific decade of observation) show 10-year survival rates of 87% to 88.5% ^[3][4].
• Age of Onset: People who develop symptoms later in life tend to have a significantly longer life expectancy. “Classical-onset” FA usually begins in childhood or early adulthood, while “late-onset” FA typically begins after age 25. In the Brazilian study, the estimated life expectancy was 71 years for late-onset FA compared to 52.2 years for classical-onset FA ^[2].
• Other Health Factors: Conditions like diabetes mellitus (a disease affecting how the body uses blood sugar) and advancing physical disability also worsen survival odds, making comprehensive medical care essential ^[3].

The Crucial Role of Cardiac Health

The biggest factor influencing life expectancy in FA is heart health. In a French study tracking FA patients referred to cardiology, cardiac complications were the cause of 80% of the recorded deaths ^[4].

Survival is closely linked to specific heart issues, including:

• Cardiomyopathy: A disease of the heart muscle that makes it harder for the heart to pump blood. Patients in studies who do not have cardiomyopathy have longer survival estimates ^[2].
• Ejection Fraction and Left Ventricular Mass: Left ventricular ejection fraction measures the percentage of blood the left ventricle pumps out with each contraction, while left ventricular mass index looks at the thickness and size of the heart muscle. A lower ejection fraction and higher mass index are associated with worse survival ^[4].
• Arrhythmias: Irregular heartbeats. In a large European registry, having a history of arrhythmic disorders nearly tripled the risk of mortality ^[3].

Cardiac Monitoring and Safety

Because the heart plays such a central role, proactive cardiac care is essential. However, not all tests are needed at the same frequency.

• Routine Tests: An electrocardiogram (ECG) (which checks the heart’s electrical activity) and echocardiography (an ultrasound of the heart’s structure and pumping function) are usually done regularly to monitor for changes ^[4][5].
• As-Needed Tests: Based on your symptoms or routine test results, a cardiologist may recommend a Holter monitor to track heart rhythms over 24-48 hours, or a cardiac MRI to look closely at heart structure, function, and severe tissue scarring (fibrosis) ^[6][7].

Early interventions with medications for heart failure or arrhythmias can improve quality of life and help manage risks ^[8][9]. Never start, stop, or change cardiac medications without discussing it with your care team.

When to Seek Urgent Care: Heart complications can become serious quickly. Seek prompt medical advice—or emergency care for severe symptoms—if you experience new or worsening shortness of breath, chest pain, fainting (syncope), persistent palpitations, leg swelling, or a sudden drop in your ability to exercise.

Disease-Modifying Therapies

The landscape of FA treatment is changing with the approval of disease-modifying therapies, such as omaveloxolone. In clinical trials, omaveloxolone was shown to significantly slow the progression of neurological symptoms—measured by a clinical scale called the modified Friedreich Ataxia Rating Scale (mFARS)—compared to a placebo or untreated patients ^[10][11][12].

It is important to know that omaveloxolone is not a cure, and approval, age eligibility, and availability vary by country. The treatment requires clinician-directed monitoring for potential side effects, including changes to liver enzymes and cholesterol levels. Furthermore, we do not yet have long-term data to know if omaveloxolone prevents heart failure or adds years to a patient’s lifespan ^[13][14]. Researchers continue to study its long-term impact.